Gefitinib (ZD1839) , ≥99% , 184475-35-2

Synonym(s):
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD1839

CAS NO.：184475-35-2

Empirical Formula: C22H24ClFN4O3

Molecular Weight: 446.9

MDL number: MFCD04307832

EINECS: 643-034-7

PRODUCT Properties

• Melting point: 119-1200C
• Boiling point: 586.8±50.0 °C(Predicted)
• Density: 1.322±0.06 g/cm3(Predicted)
• storage temp.: room temp
• solubility: Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).
• pka: 7.00±0.10(Predicted)
• form: powder
• color: white to beige
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
• InChI: InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
• InChIKey: XGALLCVXEZPNRQ-UHFFFAOYSA-N
• SMILES: N1=C2C(C=C(OCCCN3CCOCC3)C(OC)=C2)=C(NC2=CC=C(F)C(Cl)=C2)N=C1
• CAS DataBase Reference: 184475-35-2(CAS DataBase Reference)

Description and Uses

Gefitinib was introduced in Japan as a daily oral monotherapy for the treatment of inoperable or recurrent non-small cell lung cancers (NSCLC). This inhibits autophosphorylation of EGRF and blocks the cascade of intracellular events which have been implicated in the proliferation, survival and metastasis of cancer cells.

Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H319-H335
• Precautionary statements: P301+P312+P330-P305+P351+P338
• Safety Statements: 24/25
• HS Code: 29349990